🏛️ Verified NIH Record • Updated 2026-04-07
UWCCC Molecular Tumor Board Registry (NCT03023202)
UWCCC Precision Medicine Molecular Tumor Board Registry
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: University of Wisconsin, Madison
🩺 Plain-English Summary (8th-Grade Level)
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Who can join: Review the eligibility criteria below.
Location: University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Age range: 18 Years
🧪 Interventions in This Study
- PMMTB (Precision Medicine Molecular Tumor Board) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (800) 622-8922
Email: clinicaltrials@cancer.wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Neoplasms
- Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion — Durham, North Carolina
- Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil — Los Angeles, California
- A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms — Greenville, South Carolina
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) — Calgary, Alberta
- A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies — Indianapolis, Indiana
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies — Bethesda, Maryland
Explore by condition: All Hematologic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.